GlassScriptPhysician profile
John G Vansavage
NPI 1467457945
$9,341.01
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,430 · 2020: $629 · 2021: $1,806 · 2022: $566 · 2023: $344 · 2024: $3,308 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,844 · Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,843.92 |
| Food and Beverage | $1,066.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $3,230.44 | 2024-2025 | Aquabeam System |
| Boston Scientific Corporation | $2,998.77 | 2019-2025 | Lithovue, Axonics |
| Axonics, INC. | $1,682.13 | 2020-2023 | Bulkamid, Axonics |
| 180 Medical, INC. | $232.97 | 2021-2024 | Cure Ultra Catheter |
| Lumenis, INC | $185.27 | 2020-2021 | |
| Astellas Pharma US INC | $183.92 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $115.66 | 2021-2022 | |
| Ethicon US, LLC | $96.77 | 2020-2025 | Echelon; Endopath |
| Sumitomo Pharma America, INC. | $78.49 | 2023-2025 | Gemtesa |
| Endo Pharmaceuticals INC. | $74.99 | 2019-2023 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $63.18 | 2023-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $60.30 | 2021-2025 | Lynparza |
| Coloplast Corp | $53.95 | 2023-2025 | Speedicath |
| Bayer Healthcare Pharmaceuticals INC. | $53.06 | 2021-2023 | |
| Myriad Genetic Laboratories, INC. | $32.77 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.25 | 2023 | Seglentis |
| Ferring Pharmaceuticals INC. | $25.20 | 2024 | Adstiladrin |
| Olympus America INC. | $23.65 | 2023 | Itind System |
| Medtronic, INC. | $22.99 | 2025 | Interstim |
| Janssen Biotech, INC. | $22.49 | 2022 | |
| Biomerieux INC | $20.95 | 2023 | Vidas |
| Zyla Life Sciences, INC. | $19.52 | 2020 | |
| Laborie Medical Technologies Corp. | $14.13 | 2021 | |
| Abc Home Medical Supply, INC. | $14.04 | 2025 | |
| Palette Life Sciences, INC. | $8.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Vansavage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.